Glatiramer acetate in the treatment of multiple sclerosis

Bibliography

• TEITELBAUM D, AHARONI R, FRIDKIS-HARELI M, ARNON R, SELA M: Development of Copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. In: The Decade of Autoimmunin,. Shoenfeld Y (Ed.), Elsevier Science (1999):191–196.
   Google Scholar
• BORNSTEIN MB, MILLER A, SLAGLE S et al.: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl. J Med. (1987) 317:408–414.
   PubMed Web of Science ®Google Scholar
• •The first Phase II trial of glatiramer acetate.
   Google Scholar
• JOHNSON KE BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III double-blind, placebo-controlled trial. Neurology (1995) 45:1268–1276.
   Google Scholar
• ••Phase III trial that led to FDA approval.
   Google Scholar
• WOLINSKY J: Glatiramer acetate. In: Principles of Treatments in Multiple Sclerosis Hawkins CP and Wolinsky JS (Eds.), Butterworth-Heinemann, Oxford (2000): 71–94.
   Google Scholar
• NEUHAUS O, FARINA C, WEKERLE H, HOHLFELD R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 56:702–708.
   PubMed Web of Science ®Google Scholar
• GRAN B, TRANQUILL LR, CHEN M et al.: Mechanism of immunomodulation by glatiramer acetate. Neurology (2000) 55:1704–1714.
   PubMed Web of Science ®Google Scholar
• •Description of possible mechanisms in humans.
   Google Scholar
• JOHNSON KE BROOKS BR, FORD CC etal.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis (2000) 6:255–266.
   Google Scholar
• ••Dramatic decrease in number of attacksand beneficial effect on disability.
   Google Scholar
• IFNB MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. Neurology (1993) 43:655–661.
   PubMed Web of Science ®Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon beta-l-a for disease progression in relapsing multiple sclerosis. Ann. Neural. (1996) 39:285–294.
   PubMed Web of Science ®Google Scholar
• HUGHES RAC and the PRISUS STUDY GROUP: Interferon beta 1-a (rebif) in the treatment of relapsing-remitting multiple sclerosis: the clinical results of a large multicenter study. Multiple Sclerosis (1997) 3:269–274.
   Google Scholar
• FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B for THE AUSTRIAN IMMUNOGLOBULIN IN MULTIPLE SCLEROSIS STUDY GROUP: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet (1997) 349:589–593.
   PubMed Web of Science ®Google Scholar
• ACHIRON A, GABBAY U, GILAD R et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Neurology (1998) 50:398–402.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, FREEDMAN MS, ANTEL JP: Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Multiple Sclerosis (1997) 3:370–376.
   PubMedGoogle Scholar
• LISAK RP: Intravenous immunoglobulins in multiple sclerosis. Neurology (1998) 51 (Suppl. 5):525–529.
   Google Scholar
• FASSAS A, ANAGNOSTOPOULOS A, KAZIS A et al.: Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. arr. Immurrol. (2000) 20:24–30.
   Google Scholar
• COMI G, KAPPOS L, CLANET M et al.: Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis j Neural. 247:376–382.
   Google Scholar
• TEITELBAUM D, AHARONI R, SELA M, ARNON R: Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc. Nati Acad. Sci. USA (1991) 88:9528–9532.
   PubMed Web of Science ®Google Scholar
• •Important contribution to understanding the mechanism of action of glatiramer acetate.
   Google Scholar
• WEBB C, TEITELBAUM D, ARNON R, SELA M: In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur. j Immurrol. (1973) 3:279–286.
   PubMed Web of Science ®Google Scholar
• SELA M: Specific vaccines against autoimmune diseases. C.R. Acad. Li. Paris, Sciences de la vie (1999) 322:933–939.
   PubMedGoogle Scholar
• PAAS-ROZNER M, DAYAN M, PAAS Y et al.: Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc. Natl. Acad. Sri. USA (2000) 97:2168–2173.
   PubMed Web of Science ®Google Scholar
• •Similarly to glatiramer acetate in MS, a peptide suppresses myastenia gravis, underlying the specificity of vaccination also for autoimmune diseases.
   Google Scholar
• BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Medicine (2000) 6(10):1167–1175.
   Google Scholar
• KAPPOS L, COMI G, PANITCH H et al.:Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. (2000) 6(10):1176–1182.
   PubMed Web of Science ®Google Scholar
• TEITELBAUM D, MESHORER A, HIRSHFELD T, ARNON R, SELA M: Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. Immune]. (1971) 1:242–248.
   PubMed Web of Science ®Google Scholar
• HAFLER DAS, WEINER HL: Immunologic mechanisms and therapy in multiple sclerosis. Immunal. Rev (1995) 144:75–107.
   PubMedGoogle Scholar
• TEITELBAUM D, ARNON R, SELA M: Immunomoclulation of autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Nati Acad. Sri. USA (1999) 96:3842–3847.
   PubMed Web of Science ®Google Scholar
• ••Oral glatiramer acetate suppressed EAE inanimals, a study which led to a clinical study in humans.
   Google Scholar
• WEINER HL: Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc. Nati Acad. Sri. USA (1999) 96:3333–3335.
   PubMed Web of Science ®Google Scholar
• TEITELBAUM D, BEN-YEDIDIA T, TARRAB-HAZDAI R, ORR N, KARPOV-ROIKHEL O, ARNON R: Specificity of the suppressive effect of Copolymer 1. 1 Neural. (1996) 243\(Suppl. 2):585.
   Google Scholar
• BROSH N, ZINGER H, MOZES E: Copolymer 1 (Copaxone) does not affect the induction and development of experimental lupus erythematosus (SLE). Neural (1997) 244\(Suppl. 3):5113.
   Google Scholar
• ZHANG M, CHANC C, VISTICA B, HUNG V, WIGGORT B, GERY I: Copolymer 1 inhibits experimental autoimmune uveoretinitis. j Neuraimmunal (2000) 103:189–194.
   PubMed Web of Science ®Google Scholar
• SCHLEGEL PG, AHARONI R, CHEN Y et al.: A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histo-compatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc. Nati Acad. Sri. USA (1996) 93:5061–5066.
   PubMed Web of Science ®Google Scholar
• AHARONI R, SCHLEGEL PG, TEITELBAUM D et al.: Studies on the mechanism and specificity of the synthetic copolymer GLAT on graft-versus-host disease. Immunal. Lett. (1997) 58:79–87.
   PubMed Web of Science ®Google Scholar
• WEBB C, TEITELBAUM D, HERZ A, ARNON R, SELA M: Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunachemistry (1976) 13:333–337.
   PubMedGoogle Scholar
• FRIDKIS-HARELI M, TEITELBAUM D, GUREVICH et al.: Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells - specificity and promiscuity. Proc. Natl. Acad. Sri. (1994) 9:4872–4876.
   Google Scholar
• ••Glatiramer acetate binds to various MHCclass II molecules - the first step in its mechanism of action.
   Google Scholar
• FRIDKIS-HARELI M, TEITELBAUM D, ARNON R, SELA M.: Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell Immunal. (1995) 163:229–236.
   Google Scholar
• FRIDKIS-HARELI M, STROMINGER L:Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. j Immune]. (1998) 160:4386–4397.
   PubMed Web of Science ®Google Scholar
• •Proof of binding, using purified human MHC class II molecules.
   Google Scholar
• FRIDKIS-HARELI M, NEVEN JM, ROBISON RA et al.: Binding motifs of copolymer 1 to multiple sclerosis - and rheumatoid arthritis - associated HLA-DR molecules. j Immune]. (1999) 162:4697–4704.
   PubMed Web of Science ®Google Scholar
• TEITELBAUM D, AHARONI R, ARNON R, SELA M: Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sri. USA (1988) 85:9724–9728.
   PubMed Web of Science ®Google Scholar
• TEITELBAUM D, MILO R, ARNON R, SELA M: Synthetic copolymer 1 inhibits human T cell lines specific for myelin basic protein. Proc. Natl. Acad. Sri. USA (1992) 89:137–141.
   PubMed Web of Science ®Google Scholar
• •Possible mechanism of action of glatiramer acetate, at the level of competition for MHC class II.
   Google Scholar
• RACKE MK, MARTIN R, MCFARLAND H, FRITZ RB: Copolymer 1 induced inhibition of antigen-specific T cell activation: interference with antigen presentation. j Neuraimmunal. (1992) 37:75–84.
   PubMed Web of Science ®Google Scholar
• FRIDKIS-HARELI M, ROSLONIEC EF, FUGGER L, STROMINGER JL: Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc. Natl. Acad. Sri. USA (1998) 95:12528–12531.
   PubMed Web of Science ®Google Scholar
• AHARONI R, TEITELBAUM D, ARNON R, SELA M: Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sri. USA (1999) 96:634–639.
   PubMed Web of Science ®Google Scholar
• •Possible mechanism of action of glatiramer acetate at the level of competition for the specific TCR.
   Google Scholar
• LANDO Z, TEITELBAUM D, ARNON R: Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. Immund. (1979) 132:2156–2160.
   Google Scholar
• AHARONI R, TEITELBAUM D, ARNON R: T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur. I Immune]. (1993) 23:17–25.
   PubMed Web of Science ®Google Scholar
• AHARONI R, TEITELBAUM D, SELA M, ARNON R: Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Nati Acad. Sri. USA (1997) 94:10821–10826.
   PubMed Web of Science ®Google Scholar
• ••Cross-reaction between glatiramer acetateand MBP at the level of Th2 cells - possibly the main mechanism of glatiramer acetate activity.
   Google Scholar
• AHARONI R, TEITELBAUM D, SELA M, ARNON R: Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.1 Neuraimmunal. (1998) 91:135–146.
   PubMed Web of Science ®Google Scholar
• •Suppression of EAE by Th2 cells, regardless of the inducing antigen.
   Google Scholar
• KIPNIS J, YOLES E, PORAT Z et al.: T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neurophathies. Proc. Natl. Acad. Li. USA (2000) 97(13):7446–7451.
   PubMed Web of Science ®Google Scholar
• •Glatiramer acetate protects the damaged optic nerve due to T-cell immunity.
   Google Scholar
• SCHORI H, KIPNIS J, YOLES E, SCHWARTZ M: Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Nati Acad. Sci. USA (2001) 98(6):3398–3403.
   PubMed Web of Science ®Google Scholar
• ••Hopes for therapy by glatiramer acetate ofglaucoma and of acute and chronic degenerative disorders.
   Google Scholar
• TEITELBAUM D, WEBB C, BREE M, MESHORER A, ARNON R, SELA M: Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Chu. Immunal. Immunapathol. (1974) 3:256–262.
   PubMedGoogle Scholar
• ABRAMSKY O, TEITELBAUM D, ARNON R: Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. j Neural. Sci. (1977) 31:433–438.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN MB, MILLER AL, TEITELBAUM D, ARNON R, SELA M: Multiple Sclerosis: trial of a synthetic polypeptide. Ann. Neural. (1982) 11:317–319.
   PubMed Web of Science ®Google Scholar
• MEINER Z, KOTT E, SCHECHTER D et al.: Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial. In: Frontiers in Multiple Sclerosis: Clinical Research and Therapy Abramsky O, Ovadia H (Eds.), Maxtin Dimitz, United Kingdom (1997):213–221.
   Google Scholar
• JOHNSON KP BROOKS BR, COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology (1998) 50:701–708.
   Google Scholar
• MANCARDI GL, MURIALDO A, DRAGO F et al.: Localized lipoatrophy after prolonged treatment with copolymer if f Neural. (2000) 247:220–221.
   Google Scholar
• MANCARDI GL, SARDANELLI PARODI RC et al.: Copolymer-1 on serial gadolinium-enhanced MRI in relapsing multiple sclerosis. Neurology (1998) 50:1127–1133.
   Google Scholar
• •First MRI study with glatiramer acetate, indicating significant reduction in MRI lesions.
   Google Scholar
• WOLINSKY JS: Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology (1995) 45:1245–1247.
   PubMedGoogle Scholar
• COMI G, FILIPPI M, WOLINSKY JS and the EUROPEAN/CANADIAN GLATIRAMER ACETATE STUDY GROUP: European/Canadian multicentre, double blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neural. (2001) 49(3):290–297.
   PubMed Web of Science ®Google Scholar
• ••Multi-centre MRI study, with clear effectresulting from glatiramer acetate treatment.
   Google Scholar
• GE Y, GROSSMAN RI, UDUPA JK etal.: Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. Neurology (2000) 54:813–817.
   Google Scholar
• MILO R, PANITCH H: Glatiramer acetate or interferon-I3 for multiple sclerosis? CNS Drugs (1999) 11:289–306.
   Web of Science ®Google Scholar
• BORNSTEIN MB, MILLER A, SLAGLE S et al.: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology (1991)41:533–539.
   PubMed Web of Science ®Google Scholar
• •The first trial in chronic progressive MS.
   Google Scholar
• LUBLIN FD, REINGOLD SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology (1996) 46:907–911.
   PubMed Web of Science ®Google Scholar
• MILO R, PANTICH H: Additive effects of copolymer 1 and interferon beta-1 3 on the immune response to myelin basic protein. Neuraimmunal. (1995) 61(2):185–193.
   PubMedGoogle Scholar
• BROD SA, LINDSEY JW, WOLINSKY JS: Combined therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFNa) does not improve experimental allergic encephalomyelitis. Ann. Neural. (2000) 47:127–131.
   PubMedGoogle Scholar
• LUBLIN FD, REINGOLD SC: Combination therapy for treatment of multiple sclerosis. Ann. Neural. (1998) 44:7–9.
   PubMedGoogle Scholar
• MILLER A, SHAPIRO S, GERSHTEIN R et al.: Treatment of multiple sclerosis with copolymer 1 (Copaxone®: implicating mechanisms of Thl to Th2/3 immune deviation. j NeuroimmunoL (1998) 92:113–121.
   PubMed Web of Science ®Google Scholar
• QIN Y, ZHANG DQ, PRAT A, POULY S,ANTEL J: Characterization of Ti cell lines derived from glatiramer-acetate treated multiple sclerosis patients. Neuraimmunal (2000) 108:201–206.
   PubMed Web of Science ®Google Scholar
• DUDA PW, SCHMIED MC, COOK SL, KRIEGER JI, HAFLER DA: Glatiramer acetate (Copaxone ® induces degenerate, Th2-polarized immune response in patients with multiple sclerosis. j Chit. Invest. (2000) 105(7):967–976.
   PubMed Web of Science ®Google Scholar
• •Shows in human results, similar to those in animals, of glatiramer acetate treatment inducing Th2-specific glatiramer acetate responses.
   Google Scholar
• NEUHAUS O, FARINA C, YASSOURICLIS A et al.: Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Nati Acad. Sci. USA (2000) 97(13):7452–7457.
   PubMed Web of Science ®Google Scholar
• •Describes in humans shift from Thl to Th2.
   Google Scholar
• DABBERT D, ROSNER S, KRAMER M et al.: Glatiramer acetate (Copolymer 1) - specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein (MBP). Neurosci. Lett (2000) 289:205–208.
   PubMedGoogle Scholar
• DUDA PW, KRIEGER JI, SCHMIED MC, BALENTINE C, HAFLER DA: Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic polypeptide glatiramer acetate. Immunal. (2000) 165:7300–7307.
   PubMed Web of Science ®Google Scholar
• BRENNER T, ARNON R, SELA M et al.: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. j Neuraimmunal (2001) 115:152–160.
   PubMed Web of Science ®Google Scholar
• •Describes immune responses in a large number of patients from three independent clinical trials.
   Google Scholar
• FARINA C, BERGH FT, ALBRECHT H et al.: Treatment of multiple sclerosis with Copaxone (Cop): Elispot assay detects Cop-induced interleukin-4 and interferon-y response in blood cells. Brain (2001) 124:705–719.
   PubMed Web of Science ®Google Scholar
• BROSNAN CF, LITWAK M, NEIGHBOUR A et al.: Immunogenic potential of copolymer 1 in normal human lymphocytes. Neurology (1985) 35: 1754-1759.
   Google Scholar
• GRGACIC E, BERNARD CCA: Cell mediated immune response to Copolymer 1 in multiple sclerosis measured by the macrophage procoagulant activity assay. Int. Immune]. (1990) 2:718–743.
   Google Scholar
• RAGHEB S, LISAK RP: The lymphocyteproliferative response to glatiramer acetate in normal humans is dependent on both major histocompatility complex (MHC). Neural (2000) 247\(Suppl. 3) :111/119. Abstract.
   Google Scholar
• BURNS J, KRASNER LJ, GUERRERO F:Human cellular immune response to copolymer 1 and myelin basic protein. Neurology (1986) 36:92–94.
   PubMedGoogle Scholar
• LOBEL E, RIVEN-KREITMAN R, AMSALEM A, PINCHASI I: Copolymer 1. Drugs Fut. (1996) 21:131–134.
   Google Scholar
• NICHOLSON LB, MURTAZA A, HAFLER BP, SETTE A, KUCHROO VK: A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple antigens. Proc. Natl Acad. Sci. USA (1997) 94:9279–9284.
   PubMed Web of Science ®Google Scholar
• AHARONI R, TEITELBAUM D, LEITNER O, MESHORER A, SELA M, ARNON R: Specific Th2 cells are present in the central nervous system of mice protected against EAE by copolymer 1. Proc. Natl. Acad. Sci. USA (2000) 97(21):11472–11477. Glatiramer acetate specific Th2 cells penetrate the CNS by crossing the blood-brain barrier.
   Google Scholar
• HOHLFELD R, WIENDL H: The ups and downs of multiple sclerosis therapeutics. Ann. Neurology (2001) 49(3):281–284.
   PubMedGoogle Scholar